Portal de investigación
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Moreau, P
- Harrison, SJ
- Cavo, M
- Popat, R
- Hungria, V
- Salwender, H
- Suzuki, K
- Kim, I
- Spencer, A
- O'Dwyer, M
- Hong, WJ
- Jalaluddin, M
- Yang, XQ
- Pauff, JM
- Maciag, PC
- Ross, JA
- Kumar, S
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Moreau,P,Harrison,SJ,Cavo,M,De la Rubia,J,Popat,R,Hungria,V,Salwender,H et al. Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2020. ELECTR NETWORK-MAY 29-31. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2020.